Inari Medical, Inc. (NASDAQ:NARI) CEO Sells $165,870.00 in Stock

by · The Cerbat Gem

Inari Medical, Inc. (NASDAQ:NARI – Get Free Report) CEO Andrew Hykes sold 3,000 shares of the business’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $55.29, for a total transaction of $165,870.00. Following the sale, the chief executive officer now owns 439,310 shares in the company, valued at approximately $24,289,449.90. This trade represents a 0.68 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

Andrew Hykes also recently made the following trade(s):

  • On Tuesday, October 29th, Andrew Hykes sold 3,000 shares of Inari Medical stock. The stock was sold at an average price of $50.00, for a total transaction of $150,000.00.

Inari Medical Price Performance

Shares of NARI stock opened at $55.45 on Friday. The company has a market cap of $3.25 billion, a price-to-earnings ratio of -41.07 and a beta of 0.97. Inari Medical, Inc. has a 1 year low of $36.73 and a 1 year high of $66.61. The firm has a fifty day moving average price of $50.12 and a 200-day moving average price of $48.16.

Institutional Trading of Inari Medical

Hedge funds have recently bought and sold shares of the stock. Vestal Point Capital LP lifted its stake in shares of Inari Medical by 342.9% during the 3rd quarter. Vestal Point Capital LP now owns 1,550,000 shares of the company’s stock valued at $63,922,000 after buying an additional 1,200,000 shares in the last quarter. Point72 Asset Management L.P. boosted its position in shares of Inari Medical by 113.3% during the 2nd quarter. Point72 Asset Management L.P. now owns 1,481,283 shares of the company’s stock valued at $71,324,000 after acquiring an additional 786,691 shares during the last quarter. Armistice Capital LLC increased its position in Inari Medical by 353.1% in the second quarter. Armistice Capital LLC now owns 1,009,252 shares of the company’s stock worth $48,595,000 after purchasing an additional 786,501 shares during the last quarter. Jennison Associates LLC raised its stake in Inari Medical by 63.2% during the third quarter. Jennison Associates LLC now owns 1,576,641 shares of the company’s stock valued at $65,021,000 after purchasing an additional 610,468 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its position in Inari Medical by 101.3% during the third quarter. The Manufacturers Life Insurance Company now owns 795,099 shares of the company’s stock valued at $32,790,000 after purchasing an additional 400,198 shares during the last quarter. Institutional investors own 90.98% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on NARI shares. Truist Financial increased their target price on Inari Medical from $50.00 to $63.00 and gave the stock a “hold” rating in a research note on Wednesday. Stifel Nicolaus assumed coverage on shares of Inari Medical in a research report on Tuesday, September 17th. They set a “hold” rating and a $50.00 price target for the company. Canaccord Genuity Group boosted their price objective on shares of Inari Medical from $71.00 to $74.00 and gave the stock a “buy” rating in a report on Tuesday, October 29th. Needham & Company LLC reiterated a “hold” rating on shares of Inari Medical in a research note on Tuesday, October 29th. Finally, Robert W. Baird upped their price target on Inari Medical from $66.00 to $67.00 and gave the company an “outperform” rating in a report on Tuesday, October 29th. Six investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, Inari Medical has a consensus rating of “Moderate Buy” and an average target price of $61.80.

View Our Latest Stock Analysis on NARI

Inari Medical Company Profile

(Get Free Report)

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.

Featured Stories